Literature DB >> 17342657

Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis.

Barbara K Martin1, Michelle O Ricks, Michael S Forman, Douglas A Jabs.   

Abstract

BACKGROUND: In the mid-1990s, the incidence of cytomegalovirus (CMV) resistance to ganciclovir was estimated to be approximately 25% by 1 year after diagnosis of retinitis in patients with acquired immunodeficiency syndrome.
METHODS: Two hundred fifty-seven patients with CMV retinitis were enrolled in a prospective observational study during 1993-2003 and were treated with ganciclovir. Demographic characteristics and data on CMV disease, antiretroviral therapy, and ganciclovir resistance were recorded for all patients. Human immunodeficiency virus (HIV) load and CMV load were measured for patients enrolled in 1996 or later. Kaplan-Meier and Cox proportional hazards regression methods were used to examine incidence of resistance.
RESULTS: The 2-year incidence of resistance was 28% among patients enrolled before 1996 and 9% among those enrolled in or after 1996 (P=.001). All cases of resistance occurred among patients with CD4+ T cell counts <50 cells/microL, and positive CMV culture results at baseline were associated with a approximately 4-fold increase in resistance. Among patients whose CMV and HIV loads were measured, a detectable CMV load at baseline and during follow-up was associated with increased risk of resistance, but a detectable HIV load was not.
CONCLUSIONS: Rates of resistance have decreased from the high levels seen in the pre-HAART era. Better control of CMV replication may have contributed to this decrease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17342657     DOI: 10.1086/512368

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.

Authors:  Douglas A Jabs
Journal:  Am J Ophthalmol       Date:  2010-12-18       Impact factor: 5.258

2.  Detection of cytomegalovirus drug resistance mutations by next-generation sequencing.

Authors:  Malaya K Sahoo; Martina I Lefterova; Fumiko Yamamoto; Jesse J Waggoner; Sunwen Chou; Susan P Holmes; Matthew W Anderson; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2013-08-28       Impact factor: 5.948

3.  Comparison of treatment regimens for cytomegalovirus retinitis in patients with AIDS in the era of highly active antiretroviral therapy.

Authors:  Douglas A Jabs; Alka Ahuja; Mark Van Natta; J P Dunn; Steven Yeh
Journal:  Ophthalmology       Date:  2013-02-16       Impact factor: 12.079

Review 4.  The genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis.

Authors:  S H James; M N Prichard
Journal:  Infect Disord Drug Targets       Date:  2011-10

5.  CMV retinopathy in the antiretroviral therapy era: prevention, diagnosis, and management.

Authors:  Lisa Barrett; Sharon Walmsley
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

Review 6.  Antiviral drug resistance of human cytomegalovirus.

Authors:  Nell S Lurain; Sunwen Chou
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

7.  Stability of murine cytomegalovirus genome after in vitro and in vivo passage.

Authors:  Tammy P Cheng; Mark C Valentine; Jian Gao; Jeanette T Pingel; Wayne M Yokoyama
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

8.  Optimal management of cytomegalovirus retinitis in patients with AIDS.

Authors:  Michael W Stewart
Journal:  Clin Ophthalmol       Date:  2010-04-26

9.  Mortality associated with resistant cytomegalovirus among patients with cytomegalovirus retinitis and AIDS.

Authors:  Douglas A Jabs; Barbara K Martin; Michael S Forman
Journal:  Ophthalmology       Date:  2009-10-08       Impact factor: 12.079

10.  Late emergence of A594V and L595W mutations related to ganciclovir resistance in a patient with HCMV retinitis and long-term HIV progression.

Authors:  S N Slavov; F C Vilar; V M D Wagatsuma; R C Santana; A A Machado; B A L da Fonseca; S Kashima; D T Covas
Journal:  Braz J Med Biol Res       Date:  2015-08-04       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.